Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity

v3.21.2
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Balance (in shares) at Dec. 31, 2019   5,795      
Beginning balance at Dec. 31, 2019 $ 6,797 $ 6 $ 190,019 $ 50 $ (183,278)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (2,534)       (2,534)
Issuance of common stock under:          
Matching contribution to 401(k) plan (in shares)   26      
Matching contribution to 401(k) plan 155   155    
In lieu of cash compensation (in shares)   9      
In lieu of cash compensation 50   50    
Shares issued as a result of rounding due to reverse-stock split (in shares)   13      
Stock-based compensation expense 587   587    
Foreign currency translation adjustments 173     173  
Balance (in shares) at Mar. 31, 2020   5,843      
Ending balance at Mar. 31, 2020 5,228 $ 6 190,811 223 (185,812)
Balance (in shares) at Dec. 31, 2019   5,795      
Beginning balance at Dec. 31, 2019 6,797 $ 6 190,019 50 (183,278)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (11,849)        
Issuance of common stock under:          
Exercise of warrants (in shares)   723      
Exercise of warrants 1,436        
Matching contribution to 401(k) plan (in shares)   26      
Balance (in shares) at Sep. 30, 2020   8,316      
Ending balance at Sep. 30, 2020 8,401 $ 8 203,905 (385) (195,127)
Balance (in shares) at Mar. 31, 2020   5,843      
Beginning balance at Mar. 31, 2020 5,228 $ 6 190,811 223 (185,812)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (11,767)       (11,767)
Issuance of common stock under:          
Equity financing, net (in shares)   1,748      
Equity financing, net 7,082 $ 2 7,080    
Exercise of warrants (in shares)   223      
Exercise of warrants 1,436   1,436    
Issuance of warrants (2,322)   (2,322)    
Stock-based compensation expense 508   508    
Foreign currency translation adjustments (193)     (193)  
Balance (in shares) at Jun. 30, 2020   7,814      
Ending balance at Jun. 30, 2020 (28) $ 8 197,513 30 (197,579)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss 2,452       2,452
Issuance of common stock under:          
Equity incentive plan (in shares)   2      
Exercise of warrants (in shares)   500      
Exercise of warrants 5,875   5,875    
Stock-based compensation expense 517   517    
Foreign currency translation adjustments (415)     (415)  
Balance (in shares) at Sep. 30, 2020   8,316      
Ending balance at Sep. 30, 2020 8,401 $ 8 203,905 (385) (195,127)
Balance (in shares) at Dec. 31, 2020   8,349      
Beginning balance at Dec. 31, 2020 4,434 $ 8 204,376 (847) (199,103)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (3,670)       (3,670)
Issuance of common stock under:          
Equity financing, net (in shares)   3,980      
Equity financing, net 35,360 $ 4 35,356    
Exercise of warrants 3,878 $ 1 3,877    
Matching contribution to 401(k) plan (in shares)   26      
Matching contribution to 401(k) plan 152   152    
Stock-based compensation expense 356   356    
Foreign currency translation adjustments 465     465  
Balance (in shares) at Mar. 31, 2021   12,655      
Ending balance at Mar. 31, 2021 40,975 $ 13 244,117 (382) (202,773)
Balance (in shares) at Dec. 31, 2020   8,349      
Beginning balance at Dec. 31, 2020 4,434 $ 8 204,376 (847) (199,103)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (6,901)        
Issuance of common stock under:          
Exercise of warrants (in shares)   300      
Exercise of warrants 1,417        
Matching contribution to 401(k) plan (in shares)   26      
Balance (in shares) at Sep. 30, 2021   12,664      
Ending balance at Sep. 30, 2021 39,062 $ 13 245,299 (246) (206,004)
Balance (in shares) at Mar. 31, 2021   12,655      
Beginning balance at Mar. 31, 2021 40,975 $ 13 244,117 (382) (202,773)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (1,273)       (1,273)
Issuance of common stock under:          
Stock-based compensation expense 519   519    
Foreign currency translation adjustments (125)     (125)  
Balance (in shares) at Jun. 30, 2021   12,655      
Ending balance at Jun. 30, 2021 40,096 $ 13 244,636 (507) (204,046)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (1,958)       (1,958)
Issuance of common stock under:          
Equity incentive plan (in shares)   9      
Stock-based compensation expense 663   663    
Foreign currency translation adjustments 261     261  
Balance (in shares) at Sep. 30, 2021   12,664      
Ending balance at Sep. 30, 2021 $ 39,062 $ 13 $ 245,299 $ (246) $ (206,004)